None of that happened. So if you're a long-term investor who's willing to take on some risk, Viking Therapeutics is a pharma ...

Viking aims to enter the billion-dollar weight loss drug market.

In the assessment of 12-month price targets, analysts unveil insights for Viking Holdings, presenting an average target of $63.0, a high estimate of $75.00, and a low estimate of $52.00. Observing a ...

We came across a bullish thesis on Viking Therapeutics, Inc. on Value investing subreddit by Remarkable-Ad5326. In this ...

Viking Therapeutics shows promise with their VK2735 drug demonstrating significant weight loss in Phase 2 trials. Despite strong data, Viking faces intense competition and strategic challenges in a ...

Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $24.09, demonstrating a -2.92% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered ...

Viking Therapeutics' stock initially surged after positive Phase 2 data for its obesity drug, but fell after Novo Nordisk shared data on a new, oral weight loss drug. Eli Lilly and Novo Nordisk have ...

According to Benzinga Pro, Viking Therapeutics's peer group average for short interest as a percentage of float is 14.12%, which means the company has more short interest than most of its peers. Did ...

If you own or are watching Viking Therapeutics (VKTX), the past few weeks have likely caught your eye. The company’s stock took a sharp tumble after disappointing clinical trial data for its oral anti ...

The Norwegian island of Klosterøy is famous for its medieval monastery, but new research suggests it was important long before that. When you purchase through links on our site, we may earn an ...